Form 4: Dianthus Therapeutics CFO Sells Shares After Option Exercise

Dianthus Therapeutics' EVP, CFO & CBO, Ryan Savitz, executed a pre-planned sale of 114,367 common shares after exercising stock options.

Summary

• Ryan Savitz, EVP, CFO & CBO of Dianthus Therapeutics, Inc. (DNTH), reported transactions on March 31, 2026, under a Rule 10b5-1 trading plan adopted on December 30, 2025.
• Savitz acquired a total of 114,367 shares of common stock through the exercise of stock options.
• This included 74,367 shares at an exercise price of $8.44 and 40,000 shares at an exercise price of $17.88.
• Concurrently, Savitz disposed of all 114,367 shares of common stock in multiple open market sales.
• The sales occurred at weighted average prices ranging from $78.33 to $85.54 per share.
• Following these transactions, Savitz beneficially owns 0 shares of common stock directly, but retains 90,399 derivative securities (stock options).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral-to-slightly-negative event. While the transactions were pre-planned and represent a personal financial gain for the executive, the complete disposition of exercised shares reduces the executive's direct equity alignment, which can be perceived with caution by investors.

Positives

• The reporting person realized significant gains by exercising stock options at substantially lower prices ($8.44 and $17.88) and selling the shares at much higher market prices (ranging from $78.33 to $85.54).
• The transactions were executed under a pre-established Rule 10b5-1 trading plan, indicating a planned and systematic approach to managing equity compensation rather than a reaction to immediate market conditions.

Negatives

• The EVP, CFO & CBO sold all shares acquired through the option exercises, resulting in a direct beneficial ownership of 0 common shares following the reported transactions, which could be interpreted as a reduction in direct 'skin in the game' by a key executive.
• A large insider sale, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the executive's direct equity alignment with shareholders.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those by high-ranking executives like a CFO, are closely watched by investors for signals about a company's prospects. While sales under a Rule 10b5-1 plan are pre-scheduled and often for personal financial planning, a complete liquidation of exercised shares can still be interpreted as a reduction in direct equity exposure, which may warrant further scrutiny by the market.

Comparison to Industry Standards

• Insider sales under Rule 10b5-1 plans are a common practice among executives in publicly traded companies, including those in the biotechnology and pharmaceutical sectors, to manage their equity compensation while avoiding accusations of trading on material non-public information.
• The magnitude of the sale, representing all shares acquired from the exercised options, is notable. While not uncommon, it contrasts with executives who might retain a portion of their exercised shares to maintain a higher direct ownership stake, similar to practices observed at companies like Pfizer or Moderna where executives often balance personal liquidity with long-term company alignment.

Stakeholder Impact

• Shareholders: May interpret the executive's sale as a signal, potentially leading to increased scrutiny of the company's near-term prospects, despite the pre-planned nature of the transaction. The reduction in direct insider ownership could be seen as a slight decrease in alignment.

Key Dates

Recommendation

While the insider's sale was pre-planned under a 10b5-1 plan, the complete disposition of exercised shares by a key executive like the CFO, even for personal financial planning, can be a cautious signal. It suggests a reduction in direct equity exposure. Without additional company-specific news or broader market context, a 'hold' recommendation is prudent, advising investors to monitor future insider activity and company performance before making significant investment decisions.

Keywords

Dianthus Therapeutics, DNTH, Insider Trading, Form 4, Stock Options, Executive Compensation, Rule 10b5-1, Share Sale, CFO